Danese Silvio, Angelucci Erika, Malesci Alberto, Caprilli Renzo
Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy.
Med Res Rev. 2008 Mar;28(2):201-18. doi: 10.1002/med.20103.
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colonic mucosa. Over the last decade, the increasing knowledge on the pathogenic mechanisms underlying intestinal inflammation has led to the development of a number of biological agents, mainly addressed to molecules and/or pathways demonstrated to have a pathogenic role in UC. In UC, clinical course and therapeutic decisions mainly depend on disease activity and extent. While therapeutic approach to mild-to-moderate UC by using aminosalicylates and corticosteroids has been well established, treatment of severe UC is far from being satisfactory. A severe attack of UC remains a challenge to be managed jointly by gastroenterology, surgery, and intensive care units. However, the recent introduction of biological therapies has led to promising changes in the management of UC patients. Aim of this paper is to review the recent advances and future perspectives for the use of biological agents in UC.
溃疡性结肠炎（UC）是一种结肠黏膜的特发性慢性炎症性疾病。在过去十年中，对肠道炎症潜在致病机制的认识不断增加，导致了多种生物制剂的开发，这些生物制剂主要针对已证明在UC中具有致病作用的分子和/或途径。在UC中，临床病程和治疗决策主要取决于疾病活动度和范围。虽然使用氨基水杨酸类药物和皮质类固醇治疗轻度至中度UC的方法已经确立，但重度UC的治疗远不能令人满意。UC的严重发作仍然是胃肠病学、外科和重症监护病房共同应对的挑战。然而，生物疗法的近期引入已给UC患者的管理带来了有希望的变化。本文旨在综述生物制剂在UC治疗中的最新进展和未来前景。
